6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-04-19), Gamida Cell's 6-1 Month Momentum % is -54.02%.
The industry rank for Gamida Cell's 6-1 Month Momentum % or its related term are showing as below:
GMDAQ's 6-1 Month Momentum % is ranked worse than 91.51% of 1519
companies
in the Biotechnology industry
Industry Median: -1.21
vs GMDAQ: -54.02
Competitive Comparison
For the Biotechnology subindustry, Gamida Cell's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gamida Cell 6-1 Month Momentum % Distribution
For the Biotechnology industry and Healthcare sector, Gamida Cell's 6-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Gamida Cell's 6-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Gamida Cell 6-1 Month Momentum % Related Terms
Thank you for viewing the detailed overview of Gamida Cell's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.
Gamida Cell Ltd is a clinical-stage biopharmaceutical company that is pioneering a diverse immunotherapy pipeline of potentially curative cell therapy candidates for patients with solid tumors and blood cancers and other serious blood diseases. The company applies a proprietary expansion platform leveraging the properties of nicotinamide, or NAM, to allogeneic cell sources including umbilical cord blood-derived cells and natural killer, or NK, cells to create cell therapy candidates with the potential to redefine standards of care. Its primary product candidate is Omidubicel, an advanced cell therapy candidate for allogeneic hematopoietic stem cell transplant and GDA-201 is the company's lead investigational NK cell-based cancer immunotherapy product candidate.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GMDAQ has been successfully added to your